Norstella helps patients gain access to life-saving therapies. Norstella consists of prominent pharmaceutical solutions providers that have joined forces to offer a full range of consultancy services and solutions. As one organization, Norstella provides life sciences clients with the right tools and expertise to navigate complexities at each step of the drug development life cycle, from pipeline to patient. Leader for Strategy and Corporate Development

ARTiFACTS provides a simple, user-friendly platform, purpose built for academic and scientific research that leverages blockchain technology. Researchers can record a permanent, valid, and immutable chain of records in real-time, from the earliest stages of research for all research artifacts, including citing/attribution transactions. While today’s digital scholarship merely creates linkages among an artificially narrowed subset of indexed publications long after discoveries are made, ARTiFACTS focuses on capturing and linking knowledge from its initial ideation throughout the research process to informal and formal dissemination. By using the ARTiFACTS platform, researchers will be able to immutably prove ownership and existence of novel work, expand access to their research artifacts, provide and receive ‘real-time’ attribution for novel work and more comprehensively and rapidly build and demonstrate their body of scholarly contributions.To learn more, visit us at artifacts.ai and follow us on Twitter @ARTiFACTS.ai

Strategy & corporate development leader. Privately equity owned company taken public in 2021

Executive in Residence with Partners Innovation. Focus on large-scale and transformative opportunities covering AI/Machine Learning, data and content solutions, and revenue cycle management

Strategy & Corporate development leader and company officer for a $2.8B global fintech software and solutions company. Member of core executive team that drove dual track process and eventual $9.1B sale of SunGard

Responsible for strategy development, opportunity evaluation, and market engagement for Bertelsmann’s investments in the Business Information sector

Member of core executive team that led and executed all components of the carve out, marketing, and $1.25B sale of the Thomson Reuters Healthcare business

Executive team member responsible for all strategy, market intelligence, and corporate development activity for the Thomson Reuters Healthcare & Science business unit.

Executive team member responsible for all strategy, market intelligence, investment committee, and corporate development activity for the Thomson Reuters Scientific business unit.